Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(4.23)
# 415
Out of 5,127 analysts
53
Total ratings
33.33%
Success rate
40.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $75 → $74 | $23.03 | +221.32% | 3 | Dec 17, 2025 | |
| VSTM Verastem | Assumes: Overweight | n/a | $7.87 | - | 1 | Oct 16, 2025 | |
| ACLX Arcellx | Assumes: Neutral | $88 | $64.31 | +36.84% | 1 | Oct 9, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $18.83 | - | 3 | Sep 8, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $41.67 | - | 1 | Jul 17, 2025 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $72.37 | +32.65% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $9.05 | - | 2 | Jun 20, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $9.32 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $18.18 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $16.56 | -21.44% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.57 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $56.40 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $105.92 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $28.16 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.06 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $33.05 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $186.00 | +56.99% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $469.68 | -21.22% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.14 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.73 | - | 1 | May 30, 2017 |
Legend Biotech
Dec 17, 2025
Maintains: Overweight
Price Target: $75 → $74
Current: $23.03
Upside: +221.32%
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $7.87
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $64.31
Upside: +36.84%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.83
Upside: -
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $41.67
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $72.37
Upside: +32.65%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $9.05
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.32
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.18
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $16.56
Upside: -21.44%
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.57
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $56.40
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $105.92
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $28.16
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.06
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $33.05
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $186.00
Upside: +56.99%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $469.68
Upside: -21.22%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.14
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.73
Upside: -